禾信儀器(688622.SH)IPO認購結果:網上網下共棄購4106股
格隆匯9月6日丨禾信儀器(688622.SH)公佈首次公開發行股票並在科創板上市發行結果公吿,戰略配售情況:
國信資本有限責任公司繳款認購87.50萬股,繳款認購金額1548.75萬元。國信證券禾信儀器員工參與戰略配售集合資產管理計劃繳款認購175.00萬股,繳款認購金額3097.50萬元。
網上網下新股認購情況:網上投資者放棄認購數量4106股,網上投資者放棄認購金額7.27萬元;網下投資者放棄認購數量0股,網下投資者放棄認購金額0元。
網下和網上投資者放棄認購的股份全部由保薦機構(主承銷商)包銷,本次保薦機構(主承銷商)包銷股份的數量為4106股,包銷金額為7.27萬元,包銷比例為0.02%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.